American Injectables is a technology company.
American Injectables has raised $10.0M across 1 funding round.
American Injectables has raised $10.0M in total across 1 funding round.
American Injectables has raised $10.0M in total across 1 funding round.
American Injectables's investors include New Rhein Healthcare Investors.
American Injectables is a privately held contract development and manufacturing organization (CDMO) specializing in sterile injectable drug products, offering end-to-end solutions from formulation optimization and process engineering to analytical/stability services and FDA-approved manufacturing.[1][2][3][4] Based in Florida with modern facilities totaling over 33,000 sq. ft., it serves U.S. and global pharmaceutical clients by handling flexible batch sizes from under 1,000 to 150,000 units, focusing on vials, syringes, and expanding cartridge capabilities.[1][2][4] The company solves critical supply chain bottlenecks in injectables—such as delays, inflexibility, and offshoring—by providing transparent, U.S.-based production amid rising demand for drugs like semaglutide for diabetes/weight loss and therapies for chronic diseases.[2][3][7] Recent FDA approval in January 2025 validates its quality, accelerating client timelines for life-saving therapies.[3]
Established in 2020 in Florida, American Injectables was founded by industry veterans frustrated with pharma's inefficiencies, dishonesty, impossible terms, and unexplained delays that kept them from family.[1][5] Drawing from "first-hand operator experience" across leadership, board, and investors, the company emerged to prioritize transparency, teamwork, and U.S.-based quality in sterile injectables.[5] A pivotal moment came with FDA approval on January 9, 2025, under Interim CEO Travis Allen, affirming its processes and positioning it for scalable growth amid client partnerships.[3] Early traction built on state-of-the-art facilities (equipment from 2017+), enabling rapid capability expansion in a sector plagued by outdated systems.[1][2][4]
American Injectables rides the surging demand for injectable drugs driven by chronic conditions (diabetes, cancer, obesity), fueled by hits like semaglutide (Ozempic®) whose popularity via social media and endorsements has expanded markets for user-friendly pens and targeted therapies.[7] Timing is ideal as U.S. reshoring gains traction amid supply chain vulnerabilities, patent expirations enabling faster/cheaper generics (bypassing full trials via bioequivalence), and a push for domestic manufacturing to cut delays.[1][5][7] Market forces favor its nimble model: injectables' potency/rapid action suits complex diseases affecting growing populations, while flexible U.S. production addresses global shortages and regulatory hurdles.[2][3][7] It influences the ecosystem by partnering with pharma sponsors, enhancing reliability for startups and generics firms navigating formulation-to-fill-finish.[4][7]
With FDA approval secured and capabilities expanding into cartridges/packaging, American Injectables is primed to capture share in the booming injectables market. Trends like generic semaglutide competition, chronic disease prevalence, and U.S. onshoring will propel growth, potentially via strategic partnerships and larger-scale manufacturing.[3][7] Its influence may evolve as the go-to CDMO for transparent, priority service, bringing quality injectables stateside faster—reinforcing its mission to prioritize patients and clients over inefficiency.[5] This positions it as a supply chain stabilizer in pharma's high-stakes evolution.
American Injectables has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2020 | $10.0M Series A | New Rhein Healthcare Investors |